[go: up one dir, main page]

WO2016108123A3 - Pure amorphous and amorphous solid dispersion of ceritinib - Google Patents

Pure amorphous and amorphous solid dispersion of ceritinib Download PDF

Info

Publication number
WO2016108123A3
WO2016108123A3 PCT/IB2015/059657 IB2015059657W WO2016108123A3 WO 2016108123 A3 WO2016108123 A3 WO 2016108123A3 IB 2015059657 W IB2015059657 W IB 2015059657W WO 2016108123 A3 WO2016108123 A3 WO 2016108123A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous
ceritinib
solid dispersion
pure
amorphous solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/059657
Other languages
French (fr)
Other versions
WO2016108123A2 (en
Inventor
Venkata Narasayya SALADI
Vishweshwar Peddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of WO2016108123A2 publication Critical patent/WO2016108123A2/en
Publication of WO2016108123A3 publication Critical patent/WO2016108123A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to pure amorphous form of ceritinib and process for preparation thereof. Another aspect of the present application relates to amorphous solid dispersion of ceritinib and process for preparation thereof.
PCT/IB2015/059657 2014-12-17 2015-12-16 Pure amorphous and amorphous solid dispersion of ceritinib Ceased WO2016108123A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6355CH2014 2014-12-17
IN6355/CHE/2014 2014-12-17

Publications (2)

Publication Number Publication Date
WO2016108123A2 WO2016108123A2 (en) 2016-07-07
WO2016108123A3 true WO2016108123A3 (en) 2016-08-18

Family

ID=56285108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/059657 Ceased WO2016108123A2 (en) 2014-12-17 2015-12-16 Pure amorphous and amorphous solid dispersion of ceritinib

Country Status (1)

Country Link
WO (1) WO2016108123A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061120A1 (en) * 2020-09-18 2022-03-24 Dispersol Technologies, Llc Solid dispersions containing amorphous nintedanib, their synthesis and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012082972A1 (en) * 2010-12-17 2012-06-21 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012082972A1 (en) * 2010-12-17 2012-06-21 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Also Published As

Publication number Publication date
WO2016108123A2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
EP3191584A4 (en) Methods of producing mogrosides and compositions comprising same and uses thereof
WO2016011222A3 (en) Circular polynucleotides
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
WO2016001885A3 (en) Amorphous form of eliglustat hemitartarate
EP3294450A4 (en) Process to produce modified clay, modified clay produced and use thereof
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP3221843A4 (en) Efficient methodology to process wide dynamic range images
WO2016009401A3 (en) Preparation of tedizolid phosphate
WO2015092810A3 (en) Amorphous form of idelalisib
EP3280408A4 (en) Process for the preparation of dicycloplatin
WO2016038542A3 (en) Solid forms of sofosbuvir
EP3694499A4 (en) Novel process for the preparation of lifitegrast
EP3094379A4 (en) Enolase 1 (eno1) compositions and uses thereof
WO2018069941A3 (en) Polymorphic forms of venetoclax
EP3642415A4 (en) Nanolignocellulose compositions and processes to produce these compositions
EP3227298A4 (en) Process for the preparation of baricitinib and an intermediate thereof
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
EP3532055A4 (en) Compositions and methods for the production of compounds
EP3233070A4 (en) Ras-inhibiting indenyl acetamide compounds, compositions, and uses
EP3016935A4 (en) Process for the preparation of intermediate of dolutegravir
EP2989056A4 (en) Nanoiron suspension, process for the preparation thereof its use and device for the preparation of nanoiron suspension
EP3706740A4 (en) Processes to produce acalabrutinib
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15875323

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15875323

Country of ref document: EP

Kind code of ref document: A2